Spyre Therapeutics (SYRE) Income from Continuing Operations (2015 - 2026)
Spyre Therapeutics' Income from Continuing Operations was -$96.12 million in Q3 2026, compared with -$11.18 million a year earlier.
Powered by 
Analysis
Spyre Therapeutics (SYRE) Income from Continuing Operations (2015 - 2026) Analysis & Trends
On a trailing twelve-month basis, Spyre Therapeutics' Income from Continuing Operations was -$263.86 million through Sep 30, 2026; for FY2025, it was -$155.2 million.
- In earlier years, Income from Continuing Operations was -$208.02 million in FY2024, -$338.79 million in FY2023, -$83.82 million in FY2022 and -$65.8 million in FY2021.
- The Q3 2026 figure marks the lowest quarterly Income from Continuing Operations since Q2 2023.
- Per Business Quant data, SYRE's Income from Continuing Operations in the three quarters before Q3 2026 was -$36.2 million (Q2 2026), -$69.01 million (Q1 2026) and -$62.53 million (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 6.45 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 4.22 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 5.07 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 4.80 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 3.86 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 2.43 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 3.25 Bn |
| 10 | Spyre Therapeutics | 9.40 Bn | 5.68 Bn | - | -96.12 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -96.12 Mn |
| Jun 30, 2026 | -36.20 Mn |
| Mar 31, 2026 | -69.01 Mn |
| Dec 31, 2025 | -62.53 Mn |
| Sep 30, 2025 | -11.18 Mn |
| Jun 30, 2025 | -36.72 Mn |
| Mar 31, 2025 | -44.77 Mn |
| Dec 31, 2024 | -56.30 Mn |
| Sep 30, 2024 | -69.03 Mn |
| Jun 30, 2024 | -38.84 Mn |
| Mar 31, 2024 | -43.86 Mn |
| Dec 31, 2023 | -63.18 Mn |
| Sep 30, 2023 | -40.11 Mn |
| Jun 30, 2023 | -217.08 Mn |
| Mar 31, 2023 | -18.42 Mn |
| Dec 31, 2022 | -18.82 Mn |
| Sep 30, 2022 | -18.23 Mn |
| Jun 30, 2022 | -22.32 Mn |
| Mar 31, 2022 | -24.44 Mn |
| Dec 31, 2021 | -20.45 Mn |
API Access
Spyre Therapeutics Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=SYRE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "SYRE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=SYRE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();